A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX49 in Advanced/Metastatic Solid Tumors
A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HLX49 (Anti-HER2 Biparatopic and Bispecific ADC) in Participants With Advanced/Metastatic Solid Tumors
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of HLX49 in patients with advanced/metastatic solid tumors.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
In the phase Ia of this study, an accelerated titration and 3 + 3 dose escalation method will be adopted, and the patients will be administered with HLX49 at different doses via intravenous infusion. The DLT observation period lasts for 3 weeks after the first administration of HLX49.
In phase Ib of this study, the Safety Review Committee will recommend dose groups for expansion based on the safety, efficacy, and PK data of the dose escalation phase. The dose expansion part will enroll patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) who have previously failed first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars. Patients will be randomized to receive different doses of HLX49 or the active comparator (trastuzumab deruxtecan, T-DXd).
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Lin Shen
- 전화번호: +86 10 88196561
- 이메일: doctorshenlin@sina.cn
연구 장소
-
-
-
Beijing, 중국
- Beijing Cancer Hospital
-
연락하다:
- Lin Shen
- 전화번호: +86 10 88196561
- 이메일: doctorshenlin@sina.cn
-
-
-
-
-
Sunshine Coast, 호주
- Sunshine Coast University Hospital
-
연락하다:
- Hong Shue
- 전화번호: +61 7 5479 0000
- 이메일: hong.shue@schoc.com.au
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Willing and able to provide written informed consent and comply with the study protocol.
- Age: 18 to 75 years for Phase Ia; ≥ 18 years for Phase Ib. 3.Tumor Type & Prior Treatment: Phase Ia: Histologically or cytologically confirmed advanced or metastatic solid tumors that are refractory to standard treatment, or for which no standard treatment is available.
Phase Ib (GC/GEJC cohort): Histologically or cytologically confirmed advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) that has progressed during or after exactly one prior line of systemic therapy containing trastuzumab (or a biosimilar).
4.Confirmed HER2-positive status (Phase Ia: IHC 3+ or 2+; Phase Ib: IHC 3+ or IHC 2+/ISH+).
5.ECOG performance status score of 0 or 1. 6.At least one measurable lesion. 7.Life expectancy of more than 3 months. 8.Adequate washout period from prior treatments (e.g., at least 28 days for chemotherapy, radiotherapy, immunotherapy, or major surgery; at least 14 days for targeted therapy or hormone therapy) and recovery of previous treatment-related adverse events.
9.Must provide a tumor tissue sample for biomarker evaluation. 10.Adequate organ and bone marrow function as defined by protocol-specified laboratory tests.
11.Male and female participants with reproductive potential must agree to use highly effective contraception methods; female participants of childbearing potential must have a negative pregnancy test.
Exclusion Criteria:
- History of other malignant tumors within 2 years prior to the first dose (with exceptions for cured early-stage cancers like cervical carcinoma in situ or non-melanoma skin cancer).
- History of severe eye diseases (e.g., severe keratopathy or moderate to severe dry eye).
- History of or current interstitial lung disease (ILD) or non-infectious pneumonitis requiring systemic steroids.
- Severe allergic reactions to monoclonal antibodies or allergy to any component of the investigational product.
- Active systemic infections requiring intravenous antibiotics.
- Requirement for treatment with systemic corticosteroids or other immunosuppressive medications within 2 weeks prior to the first dose.
- Clinically significant cardiovascular diseases, including but not limited to: severe/unstable angina, myocardial infarction within 6 months, symptomatic congestive heart failure, LVEF <50%, poorly controlled hypertension, or clinically significant prolonged QTc interval.
- Symptomatic or uncontrolled brain or meningeal metastases, or spinal cord compression.
- Active or suspected autoimmune diseases (exceptions apply for well-controlled type 1 diabetes and autoimmune hypothyroidism on replacement therapy).
- Unhealed major wounds or anticipation of major surgery during the study.
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring frequent drainage.
- Use of strong CYP3A inhibitors or inducers within 2 weeks prior to the first dose.
- Active tuberculosis.
- Known history of immunodeficiency, including HIV, or history of solid organ transplantation.
- Active Hepatitis B (HBV) or Hepatitis C (HCV) infection (exceptions apply for stable/controlled HBV or HCV meeting specific viral load criteria).
- Pregnant or breastfeeding females.
- Subjects who are assessed as unsuitable for participating in this clinical study due to any clinical or laboratory abnormalities or other reasons by the investigator.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Ia (Dose Escalation)
Patients with advanced/metastatic solid tumors, who are refractory to standard treatment or for which no standard treatment is available. |
Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first). |
|
실험적: Ib HLX49 Dose 1 (Dose Expansion)
Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars. |
Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first). |
|
실험적: Ib HLX49 Dose 2 (Dose Expansion)
Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars. |
Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first). |
|
실험적: Ib HLX49 Dose 3 (Dose Expansion)
Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars. |
Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first). |
|
활성 비교기: Ib Trastuzumab deruxtecan (Dose Expansion)
Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars. |
Patients with good tolerability and well controlled disease will receive Trastuzumab deruxtecan via intravenous infusion once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first). |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
The Dose-Limiting Toxicity (DLT) of HLX49 within 21 days after the first Administration
기간: From first dose to the end of Cycle 1 (each cycle is 3 weeks).
|
DLT refers to the AEs that are determined to be related to the investigational product by the investigator, whose severity will affect the escalation of dose level. In this study, the DLT observation period lasts for 3 weeks (21 days) after the first administration of HLX49. |
From first dose to the end of Cycle 1 (each cycle is 3 weeks).
|
|
The maximum tolerated dose (MTD) of HLX49
기간: From first dose to the end of Cycle 1 (each cycle is 3 weeks).
|
The highest dose level, at which DLT is observed in no more than one of 6 evaluable patients, is defined as MTD of HLX49. |
From first dose to the end of Cycle 1 (each cycle is 3 weeks).
|
|
RP2D
기간: Approximately up to 24 months.
|
The recommended phase 2 dose (RP2D) of HLX49 in participants with advanced/metastatic gastric/gastroesophageal junction adenocarcinoma. |
Approximately up to 24 months.
|
|
Objective response rate (ORR) assessed by IRRC
기간: Approximately up to 24 months.
|
Percentage of participants with complete response (CR) and partial response (PR) based on independent radiographic review committee (IRRC) assessment. |
Approximately up to 24 months.
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Objective response rate (ORR)
기간: Approximately up to 24 months.
|
Percentage of participants with complete response (CR) and partial response (PR) based on investigator assessment. |
Approximately up to 24 months.
|
|
Duration of response (DOR)
기간: Approximately up to 24 months.
|
Length of time response continued based on investigator and IRRC assessment. |
Approximately up to 24 months.
|
|
Progression-free survival (PFS)
기간: Approximately up to 24 months.
|
The PFS is defined as the time from the date of enrollment to the date of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause, whichever occurred first. |
Approximately up to 24 months.
|
|
Overall survival (OS)
기간: Approximately up to 24 months.
|
Time from the date of enrollment to the date of death for any cause. |
Approximately up to 24 months.
|
|
Cmax
기간: Up to 21 days after the first dose.
|
Maximum serum concentration (Cmax) of HLX49, total antibody, and free payload. |
Up to 21 days after the first dose.
|
|
Tmax
기간: Up to 21 days after the first dose.
|
Time to maximum serum concentration (Tmax) of HLX49, total antibody, and free payload. |
Up to 21 days after the first dose.
|
|
T1/2
기간: Up to 21 days after the first dose.
|
Elimination half-life (t1/2) of HLX49, total antibody, and free payload. |
Up to 21 days after the first dose.
|
|
ADA (anti-drug antibody)
기간: Approximately up to 24 months.
|
Positive rate of anti-HLX49 antibodies (ADA). |
Approximately up to 24 months.
|
|
NAb (neutralizing antibody)
기간: Approximately up to 24 months.
|
Positive rate of neutralizing antibodies (NAb) against HLX49. |
Approximately up to 24 months.
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- HLX49-FIH101
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .